Indexed keywords
1,2,3,4,6,7,8,12B OCTAHYDRO 7 (2 MERCAPTO 3 PHENYLPROPIONAMIDO) 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID;
7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID;
ADRENOMEDULLIN;
AMLODIPINE;
ANTIHYPERTENSIVE AGENT;
ATRIAL NATRIURETIC FACTOR;
BP 1137;
BRADYKININ;
CANDOXATRIL;
CAPTOPRIL;
DIPEPTIDYL CARBOXYPEPTIDASE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ENDOTHELIN 1;
FASIDOTRIL;
LISINOPRIL;
MEMBRANE METALLOENDOPEPTIDASE;
MEMBRANE METALLOENDOPEPTIDASE INHIBITOR;
N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE;
N [[1 (2 ACETYLTHIO 3 METHYL 1 OXOBUTYLAMINO) 1 CYCLOPENTYL]CARBONYL] O METHYLTYROSINE ETHYL ESTER;
N [[1 (2 MERCAPTO 3 METHYL 1 OXOBUTYLAMINO) 1 CYCLOPENTYL]CARBONYL] O METHYLTYROSINE;
OMAPATRILAT;
RAMIPRIL;
RB 106;
SAMPATRILAT;
UK 81252;
UNCLASSIFIED DRUG;
VASOPEPTIDASE INHIBITOR;
ANGIONEUROTIC EDEMA;
ANIMAL MODEL;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COUGHING;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG POTENCY;
DRUG POTENTIATION;
ENZYME INHIBITION;
HEART FAILURE;
HORMONE METABOLISM;
HUMAN;
HYPERTENSION;
NONHUMAN;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RAT;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
1
0033011038
Vasopeptidase inhibition: A new concept in blood pressure management
(1999)
J. Hypertens. , vol.17
, Issue.SUPPL. 1
Burnett, J.C.1
2
0025775217
Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): Rational design, properties, and potential cardiovascular applications of glycopril and alatriopril
(1991)
Proc. Natl. Acad. Sci. U. S. A. , vol.88
, pp. 4210-4214
Gros, C.1
3
0002904225
Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin-converting enzyme
(Van Zwieten, P.A. and Greenlee, W.J., eds), Harwood Academic Publishers
(1997)
Antihypertensive Drugs , pp. 113-212
Robl, J.A.1
4
0029809157
Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors
(1996)
Exp. Opin. Ther. Patents , vol.6
, pp. 1147-1164
Fink, C.A.1
5
0034097941
In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor
(2000)
Hypertension , vol.35
, pp. 1226-1231
Azizi, M.1
6
0031932306
Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes
(1998)
J. Pharmacol. Exp. Ther. , vol.284
, pp. 799-805
Anastasopoulos, F.1
7
0024322626
Protection of atrial natriuretic factor against degradation: Diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan
(1989)
Proc. Natl. Acad. Sci. U. S. A. , vol.86
, pp. 7580-7584
Gros, C.1
8
0029150575
Neutral endopeptidase versus angiotensin converting enzyme inhibition in esssential hypertension
(1995)
J. Hypertens. , vol.13
, pp. 797-804
Favrat, B.1
9
0031666168
Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension
(1998)
Clin. Pharmacol. Ther. , vol.64
, pp. 439-449
Wallis, E.J.1
10
0034110537
Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans
(2000)
Hypertension , vol.35
, pp. 1148-1153
Laurent, S.1
11
0032712735
Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
(1999)
Am. J. Hypertens. , vol.12
Weber, M.1
12
0033059782
Sustained antihypertensive actions of a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects
(1999)
Am. J. Hypertens. , vol.12
, pp. 563-571
Norton, G.R.1
13
0032997846
Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure
(1999)
Cardiovasc. Res. , vol.41
, pp. 503-505
Hu, K.1
Ertl, G.2
15
0032734821
Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril
(1999)
J. Cardiovasc. Pharmacol. , vol.34
, pp. 782-790
Trippodo, N.C.1
16
0033025012
Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction
(1999)
Cardiovasc. Res. , vol.41
, pp. 544-553
Marie, C.1
17
0033862042
The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
(2000)
J. Am. Coll. Cardiol. , vol.36
, pp. 479-486
McClean, D.R.1
18
0034686963
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
(2000)
Lancet , vol.356
, pp. 615-620
Rouleau, J.L.1
19
0032728452
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: The U.S. Ecadotril Pilot Safety Study
(1999)
Am. Heart J. , vol.138
, pp. 1140-1148
O'Connor, C.M.1
22
0032456219
Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats
(1998)
J. Pharmacol. Exp. Ther. , vol.287
, pp. 567-577
Campbell, D.J.1
23
0028856125
Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin
(1995)
Hypertension , vol.26
, pp. 1160-1166
Ando, S.1
24
0031044502
The effects of the neutral endopeptidase drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides
(1997)
Br. J. Clin. Pharmacol. , vol.43
, pp. 329-332
McDowell, G.1
25
0032537519
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo
(1998)
Circulation , vol.97
, pp. 2323-2330
Ferro, C.J.1
26
0025787517
Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation
(1991)
Kidney Int. , vol.40
, pp. 188-194
Haneda, M.1
